Drug intelligence / Profile preview

PG012

Development stage: Preclinical
Lead developer: PersonGen BioTherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

PG012 is a preclinical-stage multispecific natural killer (NK) cell engager (NKCE) being developed by PersonGen-Anke Cellular Therapeutics. It is specifically designed to treat autoimmune diseases driven by auto-reactive B cells. The therapeutic mechanism of PG012 involves binding to CD16A (FcγRIIIa) on NK cells and an undisclosed antigen on the surface of pathogenic B cells. By bridging these two cell types, PG012 facilitates the recruitment and activation of NK cells to mediate the targeted lysis and depletion of autoreactive B cells, thereby mitigating the underlying cause of the autoimmune response.

Targets

FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)

Beyond the preview

Go deeper on PG012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PG012.

Explore the full profile